Chromosome band 17q21 in breast cancer: Significant association between beclin 1 loss and HER2/NEU amplification

Tiziana Negri, Eva Tarantino, Marta Orsenigo, James F. Reid, Manuela Gariboldi, Milvia Zambetti, Marco A. Pierotti, Silvana Pilotti

Research output: Contribution to journalArticlepeer-review

Abstract

Treatment success of breast cancer patients with trastuzumab alone or in combination depends not only on HER2/NEU amplification but also on PTEN and PI3K status and efficient cell death programs. In this pilot study, we found a significant association between loss of beclin 1 and HER2/NEU amplification (both on 17q21) in breast cancers. This finding was confirmed in two public copy number microarray datasets. Furthermore, there is a trend associating beclin 1 loss with TP53 mutations, PI3KCA gene gain, and PTEN mutations. Finally, the observation that beclin 1 gene loss predicted a response to trastuzumab alone or in combination with other drugs is worthy of further confirmation in larger cohorts. Our results suggest that, beclin 1 loss may contribute to genome instability and to a defective autophagy that may lead to tumoral cell death in presence of competent apoptosis or senescence pathways.

Original languageEnglish
Pages (from-to)901-909
Number of pages9
JournalGenes Chromosomes and Cancer
Volume49
Issue number10
DOIs
Publication statusPublished - Oct 2010

ASJC Scopus subject areas

  • Cancer Research
  • Genetics

Fingerprint Dive into the research topics of 'Chromosome band 17q21 in breast cancer: Significant association between beclin 1 loss and HER2/NEU amplification'. Together they form a unique fingerprint.

Cite this